Libertyville, IL, United States of America

Hongyu H Zhao

This inventor holds 11 USPTO granted patents and 10 published patent applications, plus 2 CIPO patents and 4 EPO patents. Top assignees: Abbvie Inc., Abbvie Deutschland Gmbh and Co Kg, Sparx Bioscience Limited. Active years: 2014-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hongyu H Zhao. Retrieved from https://idiyas.com/inventor/hongyu-h-zhao

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11 (Patent Applications = 10)

% Patents Active = 27.3

CIPO Patents = 2 (Patent Applications = 4)

EPO Patents = 4 (Patent Applications = 4)

Average Co-Inventor Count = 10.6

ph-index = 1

Forward Citations = 1(Granted Patents)

Location History:

North Chicago, IL (US) (2017)
Libertyville, IL (US) (2014 - 2024)

Company Filing History:

Abbvie Deutschland Gmbh and Co Kg

patents

1 out of 3

Sparx Bioscience Limited

patents

where one patent can have more than one assignee

Years Active: 2014-2024

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11970533 - Bispecific antibodies targeting human claudin 18.2 and programmed death-ligand 1 (PD-L1) (2024-04-30),

2. 9957274 - Indane inhibitors of EED and methods of their use (2018-05-01),

3. 9879033 - Modulators of 5-HT receptors and methods of use thereof (2018-01-30),

4. 9656955 - Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy (2017-05-23),

5. 9650334 - Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy (2017-05-16),

6. 9586945 - Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy (2017-03-07),

7. 9586942 - Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy (2017-03-07),

8. 9550754 - 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy (2017-01-24),

9. 9365512 - Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy (2016-06-14),

10. 9187483 - Modulators of 5-HT receptors and methods of use thereof (2015-11-17),

11. 8846951 - Modulators of 5-HT receptors and methods of use thereof (2014-09-30),

Title: Innovations and Contributions of Inventor Hongyu H Zhao

Introduction

Hongyu H Zhao is a prominent inventor based in Libertyville, IL (US). He has made significant contributions to the field of pharmaceuticals, holding a total of 10 patents. His work focuses on developing innovative compounds and methods for treating various medical conditions.

Latest Patents

Among his latest patents is a groundbreaking invention related to indane inhibitors of EED. This patent details compounds with a specific structure that can be used in pharmaceutical compositions for treating EED-related conditions, including cancer. Another notable patent involves modulators of 5-HT receptors, which includes a range of derivatives that can be utilized in treating various disease conditions. These patents highlight his commitment to advancing medical science through innovative solutions.

Career Highlights

Throughout his career, Hongyu H Zhao has worked with notable companies such as AbbVie Inc. and Abb Vie Deutschland GmbH & Co. KG. His experience in these organizations has allowed him to contribute to significant advancements in pharmaceutical research and development.

Collaborations

He has collaborated with esteemed colleagues, including Ying Wang and Huan-Qiu Li, to further enhance his research and innovations. These collaborations have played a crucial role in the success of his projects and patents.

Conclusion

Hongyu H Zhao's contributions to the field of pharmaceuticals through his patents and collaborations demonstrate his dedication to innovation and improving healthcare. His work continues to impact the medical community positively.

Profile summary based on public USPTO records.